Infections in patients with chronic kidney disease : patterns, outcomes and the role of vitamin D for future prevention by Su, Guobin
From the Department of Public Health Sciences 
Karolinska Institutet, Stockholm, Sweden 
Infections in Patients with Chronic Kidney Disease:  
Patterns, Outcomes and the Role of Vitamin D for 
Future Prevention 
Guobin Su 
苏国彬 
 
Stockholm 2019 
 
  
All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by E-print AB, 2019 
© Guobin Su, 2019 
ISBN 978-91-7831-413-3 
 
 
 
Infections in Patients with Chronic Kidney Disease: Patterns, 
Outcomes and the Role of Vitamin D for Future Prevention 
 
THESIS FOR DOCTORAL DEGREE (Ph.D.) 
By 
Guobin Su 
Principal Supervisor: 
Professor Cecilia Stålsby Lundborg 
Karolinska Institutet 
Department of Public Health Sciences 
Global Health - Health Systems and Policy: 
Medicines, focusing antibiotics  
 
Co-supervisors: 
Professor Juan Jesus Carrero 
Karolinska Institutet 
Department of Medical Epidemiology and 
Biostatistics 
 
Professor Xusheng Liu 
Guangdong Provincial Hospital of Chinese 
Medicine, The Second Affiliated Hospital, 
Guangzhou University of Chinese Medicine 
Department of Nephrology 
 
Opponent: 
Professor Bernd Stegmayr 
Umeå Universitet 
Department of Public Health and Clinical 
Medicine 
 
Examination Board: 
Professor Katarina Hjelm 
Uppsala University 
Department of Public Health and Caring Sciences 
 
Professor Knut Lönnroth 
Karolinska Institutet 
Department of Public Health Sciences  
 
Associate Professor Thomas Grenholm Tängdén 
Uppsala University 
Department of Medical Sciences 
Division of Infectious Diseases 
 
 

 
 
 
 
To Shaoping Huang, Chengxi Su, my parents Zhiwei Su, Aihong Shi,  
my parents-in-law Xiquan Huang, Xiuqiong Huang 
 and my family 

  
 
 
“When I let go of what I am, I become what I might be.” 
– Lao Tzu 
 
“以其终不自为大，故能成其大” 
–老子 
 
  
  
  
PREFACE 
Life is a journey during which we face ups and downs, twists and turns. However, your 
mind leads you to where you want to go. 
In my childhood, I suffered from recurrent tonsillitis. This granted me multiple 
opportunities to contact medical doctors and to try traditional Chinese medicine (TCM) as a 
treatment of infections without antibiotics. Curiosity about why humans get sick and how 
disease is managed drove me to apply to medical school at the entrance examination for 
higher education in China, 2004. 
I majored in integrated TCM and Western medicine, having had the opportunity to learn 
western medicine in Southern Medical University and acquire knowledge of TCM in 
Guangzhou university of Chinese Medicine. Both are located in Guangzhou city and are top 
medical universities in their fields in China. Western medicine and TCM are grounded on 
different philosophies and explain human physiology and pathology in different ways. One 
might expect that these differences might drive a medical student mad when he/she tries to 
understand both at the same time. However, they are actually well- integrated in clinical 
practice in China. The safety and efficacy of TCM has always been challenged by the 
Western world, owing to lack of knowledge. Is the current integration of TCM and Western 
medicine is good or bad? Can different perspectives improve medical care? It has always 
been my dream to broaden my knowledge, develop critical thinking and innovate 
healthcare. 
Thanks to the support of the China Scholarship Council and Guangdong Provincial 
Hospital of Chinese Medicine, the second affiliated hospital, Guangzhou University of 
Chinese Medicine, I was able to develop my critical thinking and pursue my PhD from 
2015 at Karolinska Institutet, a world famous medical university.   
As a medical doctor specialized in Nephrology, I struggled to find a research topic to fit my 
background as well as my main supervisor Professor Cecilia Stålsby Lundborg’s research 
area - antibiotic resistance. I was also uncertain about the source of data and whether TCM 
would be suitable to investigate in my PhD study.  
Luckily, I found a way with the support of Professor Cecilia, co-supervisor Professor Juan 
Jesus Carrero, Professor Xusheng Liu and Professor Bengt Lindholm. Chronic kidney 
disease (CKD) is becoming more prevalent than before as the society is ageing. As a 
progressive disease occurring in more than 10% of the adult population, CKD is an 
emerging public health problem. Hospital data of daily practice reveals that the two main 
reasons for patients with CKD being admitted to hospital are cardiovascular disease (CVD) 
and infections. Previous research interest has focused on CVD in patients with CKD. Not 
enough attention has been paid to the infections in this population. Higher rates of 
infections in patients with kidney disease and greater use of antibiotics are putting this 
population at risk of antibiotic resistance. Furthermore, these patients can potentially 
transmit resistant pathogens to patients in other sections of the healthcare facilities.  
I hope my thesis will contribute to the understanding of factors linked to the poor outcomes 
of infections in patients with CKD, and highlight the importance of future infection 
prevention for this vulnerable population as well as for public health in general.  
Now, I am at the end of my PhD study and I believe that this is just the beginning of 
another journey. I hope that the methods and critical thinking I learnt during my PhD study 
will assist the future evaluation of TCM, improve integrated medical care and promote 
better health for all. 
  
  
ABSTRACT 
Background: Chronic kidney disease (CKD) is increasingly recognized as a global public 
health problem. Patients with CKD are at high risk of infections. Frequent episodes of 
infections with greater use of antibiotics might put this population at risk of infections 
caused by resistant organisms. Thus, infection issues in patients with CKD could be related 
to another public health problem - antibiotic resistance.  
Aim: To investigate the antibiotic resistant patterns of pathogens responsible for infections, 
ascertain short-term and long-term patient outcomes during and after hospitalizations with 
infections and explore the role of vitamin D for infection prevention in patients with CKD. 
Methods: The thesis consists of two observational studies (Paper I & II), one cohort study 
(Paper III) and one systematic review and meta-analysis (Paper IV). Paper I, II & III 
explored the association between kidney function (defined as estimated glomerular 
filtration rate, eGFR) and various outcomes. These outcomes included microbial pattern 
(Paper I), prevalence of infections with multi-drug resistant organisms (MDROs) in the 
first positive microbial cultures (Paper I), intensive care unit admission (Paper II), length 
of hospital stay (Paper II), medical expense (Paper II), and mortality (Paper II & III). 
These were assessed in patients hospitalized with infections, using electronic medical 
records from four hospitals from 2012 to 2015 in China. Paper IV obtained data from 
existing literature to explore the association of infections with vitamin D status or use of 
vitamin D in patients treated with long-term dialysis. 
Results: In adult patients hospitalized with infections, the proportion of Gram-negative 
bacteria decreased while the proportion of Gram-positive bacteria increased across eGFR 
strata. Compared with the reference eGFR, lower eGFR was associated with: higher odds of 
infections by MDROs  (19% and 41% higher in those with eGFR between 30-59 
ml/min/1.73 m2 and eGFR <30 ml/min/1.73 m2, respectively) (Paper I); more than two-
fold higher adjusted odds of ICU admission, longer median length of hospital stay (P< 
0.001), inferred 20.0% higher costs in those with eGFR< 60 ml/min/1.73 m2 (P< 0.001) 
(Paper II);  progressively increased risks of cardiovascular mortality (subdistribution 
hazard ratio [SHR] 2.15 for eGFR 30-59 mL/min/1.73m2; SHR 3.19 for eGFR<30 
mL/min/1.73m2) (Paper III). In the systematic review of vitamin D and infections in 
patients treated with long-term dialysis, the risk of composite infections was 39% lower in 
those with high/normal levels of 25-hydroxy vitamin D than that in those with low levels. 
Compared to those who did not use vitamin D, the pooled adjusted risk of composite 
infection was 41% lower in those who used vitamin D (Paper IV). 
Conclusions: CKD patients hospitalized with infections have a higher risk of infections by 
MDROs, poorer in-hospital outcomes resulting in higher medical costs and increased risk 
of cardiovascular mortality in the long-run. Use of vitamin D to achieve high/normal serum 
levels of 25(OH)-vitamin D might help lowering the risk of infections in maintenance 
dialysis patients. Further research is needed to investigate the potential role of vitamin D 
therapy in infection prevention among non-dialysis dependent CKD patients.  
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1 BACKGROUND 
1.1 CHRONIC KIDNEY DISEASE (CKD): A PUBLIC HEALTH PROBLEM 
1.1.1 The definition of CKD 
Chronic kidney disease (CKD) is increasingly recognized as a global public health problem 
due to its high prevalence, high rate of complications, high health care costs and poor 
outcomes. More than 850 million people worldwide have some forms of CKD – this is 
roughly double the number of people who live with diabetes and 20 times more than those 
with cancer (1, 2).  
According to the Kidney Disease Improving Global Outcomes (KDIGO) initiative, an 
individual is classified as having CKD if abnormalities of kidney structure or function persist 
for more than three months (3). KDIGO provides a classification of severity, defining 
numerous stages of CKD based on glomerular filtration rate (GFR) and the extent of 
albuminuria (Figure 1). Although the KDIGO criteria emphasize the importance of both GFR 
and albuminuria in describing the risk of progressing to adverse outcomes, data for 
albuminuria are not always available in clinical practice for various reasons, such as under-
recognition of its importance. GFR is the best available indicator of overall kidney function, 
and represents the total amount of fluid filtered through all of the functioning nephrons per 
unit of time (4). When CKD is defined solely by GFR, we refer to a GFR of less than 60 
mL/min per 1.73 m² (5). 
Patients with CKD are at increased risk of numerous complications such as anemia, 
metabolic acidosis (reduced acid excretion by the kidneys) and CVD, which together increase 
the complexity of patient management. If complications are not well controlled, patients with 
CKD may progress rapidly to end-stage kidney disease (ESKD), which usually requires renal 
replacement therapy (RRT), either kidney transplantation or dialysis (hemodialysis or 
peritoneal dialysis), to support their life. 
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Figure 1. The Kidney Disease Improving Global Outcomes (KDIGO) classification of chronic kidney disease (CKD). 
CKD is defined as abnormalities of kidney structure or function, present for more than 3 months. KDIGO recommend that 
CKD is classified into different risk groups based on cause, glomerular filtration rate (GFR) category, and albuminuria 
category, which define the risk of progressing to adverse outcomes (such as progression to end-stage kidney disease, 
cardiovascular disease, hospitalization, acute kidney injury or death). 
 
1.1.2 Prevalence and causes of CKD 
The prevalence of CKD is rising worldwide, with the fastest growth occurring in low- and 
middle-income countries (1). The global mean CKD prevalence of stages G1-G5 is 13.4% 
(95% CI, 11.7-15.1%) (6). A recent study enrolling 12 low- and middle-income countries in 
six regions of the world, found a higher prevalence of 14.3% (95% CI, 14.0% to 14.5%) in 
general populations and 36.1% (95% CI, 34.7% to 37.6%) in high-risk populations (7). In 
terms of CKD stages 3–5, the global prevalence was 10.6% (9.2-12.2%). It varies 
substantially across countries, with values reported as low as 5.8% in Australia (8), 6% in 
Sweden (9) and 6.9% in the United States (US) (10). Notably, most prevalence data are based 
on GFR only and do not consider albuminuria (11). This means that the actual prevalence of 
CKD is probably higher. As the global population ages, the prevalence of stages 3–5 CKD in 
adults more than 65 years old is projected to exceed 28% in 2030 (12).  
When patients with CKD progress to ESKD, they require RRT, either kidney transplantation 
or dialysis. It was estimated that 2.6 million people received RRT worldwide in 2010, 
whereas the number of patients needing RRT ranged between 4.9 and 9.7 million (13). The 
global prevalence of ESKD is 280 per million people undergoing dialysis, compared with 65 
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per million people who have a functioning kidney transplant (5). Worldwide use of RRT will 
more than double to 5.4 million people by 2030, with the most growth in Asia (1.0 million to 
a projected 2.2 million) and with the most rapid relative increase projected for Latin America 
(13). 
The causes of CKD vary globally. The main causes are diabetes and hypertension in all high- 
and middle-income countries, but also in many low-income countries (5). CKD from 
glomerulonephritis and unknown causes are, on the other hand, more common in Asia and 
sub-Saharan Africa (5). 
1.1.3 Personal health and social economic burden of CKD 
1.1.3.1 Mortality 
According to the 2015 Global Burden of Disease study, the number of deaths attributed to 
CKD increased by 36.9% from 1990 to 2005 and continued to rise by 18.4% from 2005 to 
2015. CKD was ranked the 17th leading global cause of life lost in 2015 (14). Both 
myocardial infarction and cardiovascular death increase as GFR declines and the albuminuria 
increases (15, 16). Cardiovascular mortality is estimated to be 57% higher in people with a 
GFR less than 60 mL/min per 1.73 m² and 63% higher in people with microalbuminuria (17, 
18). The five-year survival of people with ESKD on dialysis is between 13% and 60% lower 
than people in the general population of similar ages (19).  
1.1.3.2 Cardiovascular complications 
The risk of having a non-fatal myocardial infarction is increased by 33% in patients with 
GFR < 60 mL/min per 1.73 m² and by 48% in those with microalbuminuria (15, 16). 
Similarly, stroke risk increases by 7% for every 10 mL/min per 1.73 m² decreases in GFR 
and by 10% for every 25 mg/mmol increases in the albumin-creatinine ratio (20). 
1.1.3.3 Quality of life 
A consistent reduction in health-related quality of life has been shown among patients with 
reductions in GFR, including those on RRT (21, 22). A recent Korean population-based study 
reported a 2% reduction in health-related quality of life for stage 2 and stage 3a CKD, a 5% 
reduction for stage 3b, and a 7% reduction for stage 4 or 5, compared with stage 1 (23).   
1.1.3.4 Medical cost and health-care services 
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The treatment of CKD and ESKD imposes substantial societal costs. Costs for CKD are not 
limited to RRT, but also include non-renal health-care costs (such as cardiovascular events, 
etc.), costs not related to health care (such as loss of productivity due to unemployment, etc.) 
and costs for patients with CKD who are not yet receiving RRT (such as costs of health 
technology, diagnostics, and medication, etc.) (24). 
RRT is the only available life-prolonging treatment for ESKD. The medical costs associated 
with the treatment of ESKD are disproportionate to the size of the population. In the US, the 
number of patients with ESKD accounts for only a small fraction (0.5%) of the US 
population, but health care expenditure for adults receiving dialysis and/or kidney 
transplantation exceed $47 billion US dollars per year or 7% of the total Medicare budget 
(25). 
In brief, CKD is a public health problem which deserves increased global attention due to its 
high prevalence, high mortality, and high level of comorbidities, associated poor quality of 
life, and large consumption of health-care resources. 
 
1.2 INFECTIONS IN PATIENTS WITH CKD: A FORGOTTEN ISSUE 
Although great progress has been made in improving the management of patients with CKD 
over the past few decades, mortality and morbidity rates remain high compared with age- and 
sex-matched individuals (24). This is predominantly due to cardiovascular disease (CVD) and 
infections (26). A great deal of attention has been paid to CVD, but the same cannot be said 
for infections (27).  
1.2.1 Higher risk of infections in patients with CKD 
Studies that associate infections with reduced kidney function are accumulating (28). All 
point estimates and most confidence intervals suggest a strong and graded association of 
infections incidence with CKD severity. An increased risk of infections associated with 
reduced estimated glomerular filtration rate (eGFR) has also been observed in outpatient 
settings. A cohort study among elderly diabetics identified in primary care in the United 
Kingdom (UK) showed that patients with decreased kidney function had increased incidence 
of lower respiratory tract infections and sepsis (29, 30). A similar association has also been 
observed in the health care ambulatory services in Sweden, which further confirmed this 
association across all types of infections (31). 
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Not only are the risks higher of mild or moderate infections in outpatient settings, but this 
association persists when it comes to severe infections that require hospitalizations. Higher 
risk of infection-related hospitalizations (IRHs) has been observed in those with reduced 
eGFR from studies in Taiwan (32), Hong Kong (33), Canada (34, 35), and the United States 
(US) (36-38). There was a graded increase of infection risk at mildly to moderately reduced 
eGFR. This pattern was observed for all-cause infections, as well as type-specific infections, 
such as pneumonia. Compared to those with eGFR of 60-104 ml/min/1.73 m2, the risk of 
hospitalization with pneumonia was 3.23 times higher in those with eGFR of 45 to 59 
mL/min/1.73 m2, 9.67 for eGFR of 30 to 44 mL/min/1.73 m2, and 15.04 for eGFR  less than 
30 mL/min/1.73 m2 (34). Data from the 2016 United States Renal Data System showed that 
the incidence of hospitalization for infections was 614 per 1000 person-years in individuals 
aged 65 years or older with any stage of CKD, which was nearly 3 times higher than the 
incidence of 214 per 1000 person-years in those without CKD (39). Although cardiovascular 
disease is still the leading cause of hospitalization (23%), infections accounts for 21% of all-
cause hospitalization, almost identical to cardiovascular disease (39). Thus, it is important to 
recognize infections as a leading cause of hospitalization among individuals with CKD. 
1.2.2  Potential mechanisms for higher risk of infection in patients with CKD 
The underlying mechanisms for higher risk of infections in patients with CKD are 
multifactorial, including patient characteristics, compromised immune system, etc. 
Many characteristics intrinsic to CKD predispose to infections, including advanced age (40, 
41), coexisting illnesses (such as diabetes and cardiovascular disease) (42, 43), complications 
(anemia, malnutrition, hypoalbuminaemia) (44), immunosuppressive therapy for kidney 
disease and increased exposure to infectious agents from frequent healthcare use (26).  
A compromised immune function is another contributor to the higher risk of infections in this 
population (45). A number of factors may contribute to the impaired immune system in CKD, 
including uremic toxin retention, inflammation, oxidative stress, and mineral-bone disorder. 
Uremic toxins, such as indoxyl sulfate, p-cresyl sulfate and trimethylamine-N-oxide, are 
metabolites of tryptophan, tyrosine and trimethylamine (46, 47). These toxins are elevated in 
patients with CKD, which can impair both leucocyte and endothelial function. Two small 
studies of hemodialysis patients suggested that increased p-cresol sulfate levels were 
associated with increased risk of infections (48, 49). When it comes to inflammation, a 
number of inflammatory cytokines such as tumor necrosis factor-alpha, interleukin-6, and C-
reactive protein) increase along with the loss of kidney function (50). Previous 
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epidemiological studies have shown that these inﬂammatory markers were associated with an 
increased risk of infections (51, 52). Oxidative stress was increased and antioxidant capacity 
was decreased among patients with CKD (53), leading to impaired immune response (54). 
Some studies suggested that bone and mineral disorders, such as vitamin D deficiency (55, 
56), and lower fibroblast growth factor 23 (57), also contributed to the increased risk of 
infections in these patients. It is well-known that there is a high prevalence of vitamin D 
deficiency [both the major circulating metabolite, 25-hydroxyvitamin D, (25(OH)D), and 
activated vitamin D (1, 25-dihydroxy vitamin D)] among patients with CKD, due to dietary 
restrictions and deficient renal 1α-hydroxylase activity (58). Vitamin D may protect against 
pathogens given that 25(OH)D supports the induction of antimicrobial peptides in response to 
both viral and bacterial stimuli (59). Moreover, vitamin D metabolites have been reported to 
induce innate antimicrobial effects, including induction of autophagy, and synthesis of both 
reactive nitrogen intermediates and reactive oxygen intermediates (60). Some observational 
studies associated higher level of 25(OH)D with a lower risk of infections in patients with 
ESKD (55, 56). 
In addition to the above mentioned potential mechanisms, RRT per se predisposes patients 
with ESKD to infections. For example, repeated needle punctures of arteriovenous fistulas 
(AVF) /grafts or dialysis catheters (peritoneal or vascular) are potential risk factors for 
infections as they disrupt the protective cutaneous barrier. Medical devices such as 
mechanical ventilation, central venous catheter, and urinary catheter are frequently used for 
CKD patients and are important sources of infections. Kidney transplant patients require life-
long immunosuppressive medication (26), which also predisposes them to infections. 
1.2.3 Treatment challenges related to infection caused by antibiotic-resistant 
bacteria in patients with CKD 
High risk of infections and greater use of antibiotics could contribute to a higher prevalence 
of infections caused by antibiotic-resistant bacteria in patients with CKD. Infections with 
resistant bacteria introduces treatment challenges in patients with CKD since resistance to 
first-line antibiotics requires the use of second and third line antibiotics with potential 
nephrotoxicity (61).  
High prevalence of colonization and infections with multi-drug resistant organisms 
(MDROs), defined as non-susceptibility to at least one agent in three or more antibiotic 
classes, such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-
resistant enterococci (VRE), have been observed in the dialysis population (62, 63).    
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1.3 STRATEGIES THAT MIGHT REDUCE THE RISK OF INFECTIONS IN 
PATIENTS WITH CKD 
Given the risks and poor outcomes associated with infections in patients with CKD and 
ESKD, strategies to prevent infections are of utmost importance. Vaccination (64) whenever 
possible could be one option to reduce the risk of infections in patients with CKD.  
In the 2013 KDIGO guideline, annual vaccination with inﬂuenza vaccine was recommended 
for all adults with CKD unless contraindicated. Pneumococcal vaccination was recommended 
for all adults with eGFR < 30 ml/min/1.73 m2 and those at high risk of pneumococcal 
infections, such as individuals with nephrotic syndrome, diabetes, or those on 
immunosuppressive drugs. In addition, revaccination was recommended for adults with CKD 
after 5 years of receiving pneumococcal vaccination (3). However, patients with advanced 
CKD and ESKD seem to have reduced responsiveness to vaccination; they develop lower 
levels of antibody titers and have a more rapid loss of antibody titers, compared to healthy 
individuals (65, 66). These means that patients with CKD might not benefit from 
vaccinations in the same way as the general population. A few studies suggested that a high-
dose or adjuvant inﬂuenza vaccine might have better eﬀectiveness than a regular vaccine in 
the elderly (67). However, the evidence is controversial in patients with ESKD, not only for 
influenza vaccination (68-70) but also for pneumococcal vaccination (71, 72). Limited data of 
vaccination is available in patients with non-dialysis dependent CKD. Both of the available 
studies were conducted almost twenty years ago and showed that patients with non-dialysis 
dependent CKD had antibody response after pneumococcal vaccination but that antibody 
levels declined rapidly within six months (73, 74). Future studies are needed to assess the 
eﬀectiveness of influenza/pneumococcal vaccination and to determine the optimal dose, 
frequency, and delivery strategy in a broader range of individuals with CKD. 
Health-care associated infections (HAIs) are more common in patients with CKD. Standard 
prevention strategies, such as good hand hygiene, prompt removal of devices (such as central 
venous catheter, and urinary catheter, etc.) and maximal barrier precautions during treatment 
procedures, are critical for minimizing the risk of HAIs, especially in those with CKD (75).  
 
1.4 PROFILE OF CHINA 
1.4.1 Country demographics 
The People's Republic of China (PRC) is located in East Asia. The country is bounded by the 
Yellow Sea and the East China Sea to the east; Vietnam, Laos, India, Bhutan and Nepal to the 
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south; Pakistan to the southwest; and Afghanistan, Tajikistan, Kyrgyzstan and Kazakhstan to 
the west; Mongolia, Russia and North Korea to the north. With a population of around 1.404 
billion in 2017 according to World Population Prospects from the United Nations, China is 
the world's most populous country. Covering approximately 9,600,000 square kilometers, it is 
the third largest country by total area (76).  
1.4.2 Patients with CKD in China 
The occurrence of CKD in adults in China is similar to that in other low or middle-income 
countries, with a cross-sectional survey of a nationally representative sample finding a 
prevalence of 10.8% (10.2% - 11.3%) (77). The number of patients with CKD in China is 
therefore estimated to be around 120 million, the highest total for a single country (78). 
Diabetes is becoming the leading cause of CKD in China (79). Furthermore, China is 
confronting the increased threat of ESKD. Data on RRT among 3 million urban insured 
employees in Nanjing, revealed that from 2005 to 2014, the prevalence of patients 
undergoing RRT increased and, importantly, the urban population doubled (80).  
1.4.3 Healthcare system reform in China 
The National Health Commission of PRC oversees the health services system and the health 
needs of the Chinese population. All major medical facilities are run by the government, but 
some private health services have emerged in recent years.  
During the period from 1949 to the early 1980s, the Chinese government owned, funded, and 
ran all hospitals. Physicians were employees of the state. There was no health insurance since 
health services were nearly free of charge at that time (81). 
After economic reforms in around 1980, China reduced the role of government in all 
economic and social sectors, including health care. The government continued to own 
hospitals but exerted little control over the behavior of health care organizations, which acted 
like for-profit entities (82). Physicians working for hospitals received a large number of 
bonuses for increasing hospital profits. However, this market reform resulted in public anger, 
lack of access to health care for those unable to pay the increased medical cost, distrust 
toward health care institutions and professionals and even in physical attacks on physicians 
(82). 
To address the discontent with health care, in 2003 the government of China took the step of 
introducing a health insurance scheme covering in-hospital expenses for rural residents. A 
profound health care reform was then announced in 2009, with the goal of providing 
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affordable and equitable basic health care for all by 2020. The reform is ongoing and 
anchored in five interdependent areas: Expanding coverage to insure more than 90% of the 
population, establishing a national essential medicines system to meet all citizen’s  primary 
needs for medicine, piloting public hospital reforms, improving the primary care delivery 
system to provide basic health care and managing referrals to specialist care and hospitals, 
making public health services available and equal for all (83). 
1.4.3.1 Insurance and payment system in China 
During the 2009 healthcare reform, China introduced insurance systems for urban residents 
(Urban Employees Basic Medical Insurance, UEBMI, and Urban Resident Basic Medical 
Insurance, URBMI), farmers (New Rural Cooperative Medical Service) and those living in 
poverty in both urban and rural areas (Medical Assistance Program), to achieve universal 
coverage (84). By 2012, a government-subsidized insurance system provided 95% of the 
population with modest but comprehensive health coverage, with funding sourced from tax 
and premiums (82).  
Local government financing is allocated at the provincial level every year, based on the the 
number of hospital beds. However, government allocations cover less than 10% of funding 
for most public hospitals (85). The major proportion (more than 90%) of funds for public 
hospitals comes from fees for medical services and medicines.  
The fee-for-service (FFS) payment system was once the prevailing method of payment in 
Chinese public hospitals, which reimburses hospitals retrospectively based on clinic visits, 
examinations and treatment programs. Under the FFS payment system, improper incentives 
are largely responsible for the rising costs of health care. For public hospitals to obtain their 
funds, physicians were encouraged to prescribe expensive or profitable medications, which 
were not always beneficial to patients. This behavior drove the rising medical costs (86). 
Along with limited financial resources, the rapid increase in health care costs prompted the 
decision to move away from a retrospective FFS payment model to a prospective payment 
system – Diagnosis-related group (DRGs)-based case-mix funding system (or so-called single 
disease reimbursement payment) (87). Ideally, DRGs are "diagnosis-related" groups of 
patients that are homogenous in terms of clinical significance and resource consumption. 
Therefore, individuals with the same DRG classification are medically and economically 
similar. Under a DRG-based case-mix payment system, hospitals receive a fixed rate for each 
admission according to a patient's DRG category. The pre-defined fee for treating patients in 
a single DRG category sets a limit on the overall expenses for individual patients regardless 
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of the actual cost of caring for the individual. If the actual medical expenses exceed the pre-
defined fee, the excess is borne by the hospital. Ideally, hospitals should increase the 
efficiency and quantity of medical services and contain costs to make a profit (87).   
1.4.3.1 Antibiotic resistance and policy in China 
Antibiotic resistance and overuse of antibiotics have become a public health crisis in China. 
China has the world’s most rapid growth rate of resistance with high resistance rates of the 
most common bacteria (88). Methicillin-resistant S. aureus, Extended Spectrum Beta-
Lactamase (ESBL)-producing Enterobacteriaceae and carbapenem-resistant Acinetobacter 
baumannii account for more than 50% of microbial isolates (89). Several factors are 
involved, including misuse and overuse of antibiotics among humans as well as in livestock 
(90). The total antibiotic usage in China in 2013 was approximately 162,000 tons, including 
human use (48%) and use in animals (52%) (91), which was almost half of 
the antibiotic usage worldwide. As a last resort treatment of bacterial infections, colistin is not 
yet available for hospital use in China. However, mcr-1-containing plasmid-mediated 
colistin-resistant Enterobacteriaceae has been identified in clinical samples and animals in 
China (92, 93). This indicates that antibiotics use in agriculture in China is one of the driving 
forces of antibiotic resistance. Overall, these data suggest that China is one of the world's 
leading countries with serious problems in terms of antibiotic misuse and antibiotic 
resistance. 
To cope with the problem of antibiotic resistance, the government of China introduced an 
essential medicines programme for public health-care institutions in 2009 to reduce irrational 
drug use (eg, over-prescription of antibiotics) (83). In 2010, the Health Ministry of China 
separated doctors’ pay from prescription drug sales. Since 2012, China has run a national 
campaign in hospitals to promote the rational use of antibiotics. Drugs with the highest 
resistance rates can be prescribed only by specialists (83). Those who violate the rules can 
lose prescription rights or their medical license (94). In 2016, the Chinese Government 
announced a national action plan (NAP) to combat antimicrobial resistance. The China NAP 
highlights four key strategies: 1) Coordination of 15 ministries involved in the regulation of 
antibacterial agents and antimicrobial resistance control at a national level; 2) Implementation 
of a “one-health concept” integrating agriculture, health, and environmental protection 
departments; 3) Substantial financial investment for improvement of facilities, surveillance, 
and research; and 4) Promotion of international collaborations (95).   
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1.5 THESIS RATIONALE AND KNOWLEDGE GAP 
In patients with CKD, susceptibility to infections results in the more frequent use of 
antibiotics (106) and more hospitalizations (29, 31, 35), which also increases their exposure 
to microbes, including MDROs (107). The focus has been placed mainly on dialysis patients 
in previous studies (67, 68, 108, 109). However, it is unclear whether infections caused by 
MDROs are more common in patients with non-dialysis dependent CKD (NDD-CKD) than 
those in the non-CKD population; this needs to be confirmed. The higher infection risk 
among CKD patients might also contribute to the emergence and spread of MDROs. This 
might place the global population at risk of infections caused by resistant bacteria.  
There has been little exploration on whether in-hospital outcomes (admission rates, lengths 
of stay, mortality during admission) or economic burden differ between these patients. This 
has implications for how medical resources are allocated at a societal level, especially in the 
context of the DRGs in China: Payment/reimbursement to the hospital from government is 
the same if patients are admitted for the same cause, regardless of comorbidities (85). 
Infections might also be associated with an increased risk of cardiovascular events (96-98). 
Previous studies have shown that infections leads to increased risk of cardiovascular events 
and cardiovascular mortality in dialysis patients (43, 99). It is unclear whether, and to what 
extent, reduced kidney function predisposes to higher cardiovascular-related mortality in the 
context of infections. Knowledge of the relationship between kidney function and cause-
specific mortality in the context of infections may help to better inform and tailor treatment 
and prevention strategies. 
When it comes to infection preventive strategies, vitamin D seems to have promising 
potential. In the general population, studies show that a higher level of 25(OH)D and the use 
of vitamin D supplements are associated with a lower risk of infections (100, 
101). However, observational studies have shown conflicting results in dialysis patients (55, 
56, 102-107). We therefore found it useful to undertake a systematic review and meta-
analysis on the association between serum concentrations/use of vitamin D and infection 
risk in this population.  
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2 AIM AND OBJECTIVES 
2.1 OVERALL AIM  
To investigate the antibiotic resistant patterns of pathogens responsible for the infections, 
ascertain short-and long-term outcomes during and after hospitalizations with infections and 
explore the role of vitamin D for infection prevention in patients with CKD.  
2.2 SPECIFIC OBJECTIVES 
1) To describe microbial patterns of infections and explore the association between kidney 
function at admission and the risk of infections by multi-drug resistant organisms in 
patients hospitalized with infections (Study I). 
2) To compare the short-term outcomes (in-hospital mortality, the rate of intensive care 
admission, length of hospital stay and medical expense) of infection-related 
hospitalizations between patients with and without CKD (Study II). 
3) To characterize the cause of death and explore the association between kidney function at 
admission and long-term cause-specific mortality in patients hospitalized with infections 
(Study III). 
4) To explore the association between circulating vitamin D concentrations and risk of 
infections in CKD patients treated with chronic dialysis and to explore whether the use of 
vitamin D supplements or vitamin D receptor activators affects these outcomes (Study 
IV). 
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To fulfill the aim and objectives, this thesis contains four studies (Figure 2).
 
Figure 2. Study framework 
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3 METHODS 
3.1 OVERVIEW OF THE STUDY DESIGN 
The study I and II were observational studies based on data collected from the 
electronic health records in Guangdong provincial hospital of Chinese medicine 
(GDHCM), Guangzhou city, China. Study III was a cohort study using data from the 
electronic health records from GDHCM and linked with data from the death registry at 
the Center for Disease Control and Prevention, China. Study IV was a systematic 
review and meta-analysis of existing literature (Table 1.).    
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Table 1. Overview of paper’s topics and methods 
Topics Study design Study population Exposure/comparison Outcomes Data analysis 
Microbial 
pattern & 
Antibiotic 
resistance 
(Study I) 
 
Observational 
study 
20,642 adult patients from 4 hospitals in China from 
2012-2015, who were (1) hospitalized with a 
discharge diagnosis of infection, (2) had a serum 
creatinine measurement at admission, (3) not on 
dialysis or kidney transplantation. and (4) had a 
positive microbial culture result in which the type of 
sample matched the type of infection. 
Estimated glomerular filtration rate 
(eGFR, ml/min/1.73m2)  
• 60-104 (Reference) 
• vs. 30-59  
• vs. <30  
Multidrug-resistant organism The 
multivariable 
logistic 
regression model 
Short-term 
outcomes 
(Study II) 
 
Observational 
study 
6,283 adult patients from 4 hospitals in China from 
2012-2015, who were (1) hospitalized with a 
discharge diagnosis of infection, (2) had a serum 
creatinine measurement 1-12 months at outpatient 
visits before index hospitalization, (3) not on dialysis 
or kidney transplantation. 
eGRF (ml/min/1.73m2) 
• ≥60 (Reference) 
• vs. <60 
 
• In-hospital mortality 
• Intensive care unit 
admission 
• Length of hospital stay 
• Medical costs  
 
Mixed-effects 
logistic 
regression model 
and generalized 
linear model 
Long-term  
outcomes 
(Study III) 
 
Cohort study 40,524 adult patients from 4 hospitals in China from 
2012-2015, who were (1) hospitalized with a 
discharge diagnosis of infection, (2) had a serum 
creatinine measurement at admission, (3) not on 
dialysis or kidney transplantation. 
eGRF (ml/min/1.73m2)  
• ≥60 (Reference) 
• vs. 30-59  
• vs. <30 
• All-cause mortality 
• Cardiovascular mortality 
Multivariable 
Cox regression 
and competing 
risk analyses 
Prevention 
strategies 
(Study IV) 
Systematic 
review and 
meta-analysis 
Literature until Dec 2017 who reported (1) patients 
in long-term dialysis, (2) either had records of levels 
of serum 25-hydroxy vitamin D or use of vitamin D, 
(3) had infections as outcomes. 
• Serum of 25(OH)VitD  
High vs. Low 
• Nutritional vitamin D or 
vitamin D receptor activator  
Use vs. non-use 
Infection-related outcomes 
• Infections 
• Infection-related 
hospitalization 
• Infection-related mortality 
Random-effects 
meta-analysis 
Meta-regression 
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3.2 STUDY SETTINGS (STUDY I, II, III) 
Data used in Studies I, II and III were from GDHCM, The Second Affiliated Hospital 
of Guangzhou University of Chinese Medicine. GDHCH is located in Guangzhou city.  
Guangzhou is the capital city of the Guangdong province, located in the southern part 
of China, 120 km north-northwest of Hong Kong and 145 km north of Macau. It has a 
population of 13,501,100 residents as of 2015 (108). As the third largest city in China in 
terms of total economic volume, Guangzhou serves as one of the major transportation 
hubs and one of the leading commercial and manufacturing cities in mainland China. 
GDHCM is one of the oldest and the largest hospitals of Chinese medicine. It has four 
branches located in different districts of Guangzhou city and serves as one of the main 
referral centers for these districts. GDHCM provides both modern medicine and 
Chinese medicine such as Chinese herbal medicine, acupuncture and medicinal 
massage to patients, according to patients’ parallel diagnosis of modern medicine and 
Chinese medicine. It has over 70,000 inpatients and seven million outpatient visits per 
year and is one of the leading hospitals in terms of outpatient visits in mainland China. 
The four hospital branches share the same electronic medical record (EMR) database, 
developed by International Business Machines Corporation (IBM), which includes all 
inpatient and outpatient medical records as well as costs invoiced.   
  
Figure 3. Study location  
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3.3 STUDY POPULATION (STUDIES I, II, III) 
3.3.1 The study population (Definitions common to Studies I, II, III) 
Patients were eligible for inclusion in our studies if they were adults (≥18 years), had at 
least one discharge diagnosis of infection according to the International Classification 
of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) (Appendix Table S1) 
(109), between August 2012 and December 2015, regardless of diagnosis order. We 
excluded those patients who had been undergoing renal replacement therapy (RRT - 
kidney transplantation or dialysis) before the date of admission. Since the exact 
infection date was unknown, the date of admission was used as the proxy date for an 
infection. 
A number of discharge diagnoses were not considered as acute infections in Studies I, 
II, III: those commonly found only in infants or children, pregnancy-related infections, 
delivery-related infections, ear infections, eye infections, thyroiditis, pituitary gland 
infections, oral/mouth infections, pancreatitis, chronic infections such as chronic 
hepatitis B and C, HIV (human immunodeficiency virus) infections, cholecystitis 
associated with cholelithiasis/choledocholithiasis, parasitic or protozoal diseases, 
sexually transmitted infections, and device-dialysis related infections. 
The selected infections were classified broadly into mutually exclusive categories: 1) 
Respiratory tract infection, including pneumonia; 2) Genitourinary infections, including 
urinary tract infections; 3) Bloodstream infections or sepsis; 4) Abdominal infections; 
5) Skin and soft tissue infections; 6) Cardiovascular infections; 7) Musculoskeletal 
infections; 8) Nervous system infections; 9) Other infections of interest. 
3.3.2 Additional inclusion criteria for Study I 
In Study I, we only included those who had 1) serum creatinine measurement available 
at admission; 2) a positive microbial culture result in which the type of sample aligned 
with the type of infections (Appendix Table S2). Only the first admission record was 
used for patients with multiple hospital admissions. In case of multiple infection 
diagnoses during the same hospitalization, only one infection diagnosis was used and 
only if the type of first positive culture matched the discharge diagnosis of infections. 
For example, the first positive midstream urine culture should match to urinary tract 
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infections; Bacteraemia/sepsis was valid if it had a positive culture of any type. Thus, 
each hospitalization had a unique culture-confirmed infection diagnosis.   
3.3.3 Additional inclusion criteria for Study II  
In Study II, we only included those with at least one serum creatinine measurement at 
outpatient visits between one and twelve months prior to hospitalization with infections. 
In case of multiple outpatient serum creatinine, we chose the eGFR value closest in 
time to the hospitalization (1-12 months before) as a proxy for kidney function. Since 
we included only those with serum creatinine at the outpatient visit, no one was lost to 
follow-up at the time of discharge from GDHCM. 
3.3.4 Additional inclusion criteria for Study III 
In Study III, we only included those who had at least one serum creatinine 
measurement available at admission. All patients were followed until their death. Data 
were censored on 31 August 2016 if patients were still alive. Only the first admission 
record was used in patients with multiple hospital admissions.  
 
3.4 EXPOSURE: ESTIMATED KIDNEY FUNCTION 
We used the eGFR as an indicator of kidney function in Studies I, II and III. eGFR 
was estimated by age, sex, serum creatinine concentration and race, according to the 
established Kidney Disease Improving Global Outcome initiative, and calculated by the 
CKD-EPI (CKD Epidemiology Collaboration) formula (110). Serum creatinine 
concentration was assessed by the enzymatic method. The same standardized procedure 
was used in all laboratories in the different branches of GDHCM. The standard and 
quality of the laboratory in GDHCM were certified by the International Organization 
for Standardization, ISO 15189. 
3.4.1 Categories of eGFR at admission (Studies I, III) 
We estimated eGFR using the serum creatinine at admission. In clinical practice, eGFR 
at the time of admission provides an important indicator of kidney function to help 
inform clinical decision-making, although it does not differentiate between acute and 
chronic kidney dysfunction. In Study I, four categories of eGFR were studied: 
eGFR≥105, 60-104, 30-59, and <30 ml/min/1.73 m2, with eGFR of 60-104 ml/min/1.73 
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m2 serving as the reference group as this range showed the lowest risk of infections and 
eGFR≥105 ml/min/1.73 m2 might indicate malnutrition (34). 
In Study III patients were divided into three categories of eGFR: ≥ 60, 30-59 and < 30 
mL/min/1.73m2. eGFR ≥ 60 served as the reference group since this group was 
observed to have the lowest risk of death in previous studies (111, 112).  
3.4.2 Categories of eGFR at outpatient visits (Study II) 
In Study II, we first identified patients hospitalized with infections and traced them 
back to find those with a serum creatinine value at outpatient visits. In case of more 
than one value, we chose the eGFR value closest in time to the hospitalization (1-12 
months prior to the hospitalization) as a proxy for kidney function. The reason for this 
was to have an estimation of renal function from serum creatinine tests not influenced 
by the acute nature of the hospitalization. CKD was defined as eGFR <60 ml/min per 
1.73 m2, while non-CKD was defined as eGFR ≥ 60 ml/min per 1.73 m2. 
 
3.5 OUTCOMES 
3.5.1 Multidrug-resistant organisms (MDROs) (Study I) 
According to the international expert proposal initiative by the CDC and European 
Centre for Disease Prevention and Control (ECDC), MDROs mainly focused on five 
bacteria, including Enterococcus spp., Enterobacteriaceae (other than Salmonella and 
Shigella), Staphylococcus aureus, Pseudomonas aeruginosa and Acinetobacter spp., 
and acquires non-susceptibility to at least one agent in three or more antimicrobial 
categories. Non-susceptibility refers to either a resistant, intermediate or non-
susceptible result obtained from in vitro antimicrobial susceptibility testing (113). The 
first positive culture was used to avoid the influence of the initial antimicrobial therapy 
on culture result and different culture results during the same hospitalization. 
According to Clinical and Laboratory Standards Institute (CLSI) procedures (114, 115), 
a number of procedures were applied to identify bacteria, including sampling, culture, 
microbiological tests based on Gram staining, microscopic observation of bacterial 
morphotypes, characteristics in culture medium and various specific biochemical 
reactions. Antibiotic susceptibility testing and antibiotics panel used for susceptibility 
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testing were also performed according to CLSI procedures, CLSI guidelines and local 
prescription pattern (114). Susceptibility analysis system (MicroScan® WalkAway® 96 
Plus; Beckman Coulter, Brea, CA) was used to determine the minimum inhibitory 
concentrations (MICs). The antibiotic susceptibility was interpreted using the CLSI 
MIC breakpoints at the time the test was conducted (114). The standard and quality of 
the laboratory in GDHCM are certified by the International Organization for 
Standardization, ISO 15189. 
3.5.2 In-hospital outcomes (Study II) 
In-hospital outcomes included in-hospital mortality, admission to an intensive care unit 
(ICU), the length of hospital stay (LOSH) and medical costs. All the data mentioned 
above were extracted from the EMR of GDHCM. Medical costs during a 
hospitalization were extracted from the billing system in GDHCM. Total medical costs 
included investigation-related costs (considering laboratory, imaging, pathology and 
consumable items), ward-related costs (considering all other cost incurred while in the 
ward), cost of non-surgical therapies (acupuncture, physiotherapy, injection, etc.), costs 
of surgical therapies (including anesthesia and related materials) and medicine costs. 
3.5.3 Cause-specific mortality (Study III)  
Mortality data was linked with the death registry from the CDC in Guangdong 
province, China. Cause of death was classified into five broad categories using ICD-10-
CM: cardiovascular disease, acute infections, cancer, chronic kidney disease and other 
cause of death. The death registry in CDC had comprehensive records of deaths in 
Guangdong province, including time of death and cause of death. The cause of death in 
the registry of the CDC database was determined by the attending physician, medical 
examiner or other certifiers. The codes of death used in the analysis were adapted from 
the previous studies (116, 117) and are listed in Appendix Table S3. 
 
3.6 COVARIATES 
Age (categorized as 18–44, 45–59, 60-74 and ≥ 75 years old), sex and comorbidities 
were extracted from the EMR database of GDHCM. Comorbidities were ascertained 
from the discharge diagnosis according to the classification of Charlson comorbidities 
index using an established ICD-10 algorithm (118), including congestive heart failure, 
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myocardial infarction, cerebrovascular disease, peripheral vascular disease, dementia, 
chronic pulmonary disease, peptic ulcer disease, rheumatologic disease, hemiplegia or 
paraplegia, liver disease, diabetes, and cancer/malignancy. According to the GDHCM 
policy, discharge diagnosis was required to include all the comorbid conditions from 
patients’ medical history. 
Infection-related hospitalizations were sub-classified as community-acquired infection-
related hospitalizations (CAIRHs), health care-associated infection-related 
hospitalizations (HAIRHs) and undefined infection-related hospitalizations (UIRHs). 
CAIRHs were defined as those with infection diagnosis at admission. HAIRHs were 
defined as those with onset of infections after 48 hours after admission (119) and 
confirmed by health care-associated infection report in the database which was audited 
by infection professionals in GDHCM. UIRHs were those who did not fulfill any of the 
above criteria. 
 
3.7 SYSTEMATIC REVIEW METHODOLOGY (STUDY IV) 
The systematic review and meta-analysis was conducted in accordance with the 
Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 
guidelines (120) and Meta-analysis of Observational Studies in Epidemiology 
(MOOSE) (121). The protocol was registered with the PROSPERO International 
Prospective Register of Systematic Reviews 
(http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018084779). 
3.7.1 Inclusion and Exclusion Criteria 
The inclusion criteria were presented according to the Study design, Population, 
Intervention, Comparison and Outcomes (S-PICO) model as follow: 1) Intervention 
studies (randomized controlled trials or non-randomized intervention studies) or case-
controlled studies or cohort studies; and 2) end-stage kidney disease patients (age ≥ 18 
years old) undergoing hemodialysis or peritoneal dialysis; and either 3) Available data 
for different concentrations of serum 25-hydroxy vitamin D [25(OH)D, the major 
circulating vitamin D metabolite]; or (4) For drug use studies, at least one group 
receiving either a vitamin D receptor activator (VDRA) (Paricalcitol, Doxercalciferol, 
Calcitriol, Alfacalcidol, Maxacalcitol, Falecalcitriol) or nutritional vitamin D 
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(D2/ergocalciferol and/or D3/ cholecalciferol) supplements, whilst the other groups 
received placebo or no treatment; & 5) Available data for outcomes of interest: 
Infection-related mortality, risk of infection-related hospitalization, or risk of any 
infections. We excluded editorials, reviews, case reports and case series articles. Since 
the aim of this analysis was to compare outcomes for patients with high/normal versus 
low serum 25(OH)D levels, we excluded studies where original individual data were 
not accessible to permit categorization of serum 25(OH)D levels.  
3.7.2 Information sources and search strategies  
The search was conducted using  four English-language databases [Cochrane Central 
Register of Controlled Trials, Pubmed, (Appendix Table S4), EMBASE (Elsevier), 
Web of Science] and three Chinese databases [Chinese National Knowledge 
Infrastructure (CNKI), China Biology Medicine disc (CBM), Wanfang Data 
Knowledge Service Platform (WanFang)], from inception until Dec 31, 2017. We also 
kept track of the other resources such as conference proceedings in order to identify 
“grey literature”. The search strategy was adapted from the published Cochrane review 
[12] keeping the key terms: ‘vitamin D’, and ‘dialysis’ and ‘infection’.  
3.7.3 Data extraction 
We used predefined forms to extract data from the included studies, including study 
design, region, participants, concentration or level used as a cut-off to define vitamin D 
deficiency, intervention details (types of vitamin D, dose, frequency, duration, modes of 
administration if applicable), comparison, outcomes, results and follow-up period. For 
each study, relative risks (RR) were extracted including incidence rate ratios, odds 
ratios (OR) and hazard ratios (HR), as well as risk assessments based on the most fully 
adjusted models. If RR was not available in the studies, the numbers or incidences of 
the outcomes were extracted to calculate the RRs. 
3.7.4 Risk of bias assessment of included studies 
The risk of bias of each included randomized control trials was assessed using the 
Cochrane Collaboration's tool. For cohort and case-controlled studies, the Newcastle-
Ottawa Scale (NOS) tool was used (122). In the case of any disagreement, a third 
author also assessed the study.  
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3.8 DATA ANALYSIS 
Numerical variables were summarized as mean with standard deviation, or median with 
interquartile range, as appropriate. Categorical variables were summarized using 
proportions. Differences in baseline characteristics and the proportion between or 
among groups were compared using the Mann-Whitney U test, analysis of variance, 
chi-square test, Fisher´s exact test, or Wilcoxon rank-sum test, as appropriate. All the 
data extracted from electronic medical records databases in Studies I and II were 
complete, with no missing data and loss to follow-up. In Study III, we assumed an 
absence record in the death registry to indicate that the patients were alive and 
considered censored on 31 August 2016. A P-value < 0.05 was considered significant. 
All statistical analyses were performed using STATA version 14.2 (StataCorp, College 
Station, TX, USA). 
3.8.1 Statistics in Study I 
For the odds ratio (OR) of MDROs, we used multivariable logistic regression adjusted for 
age group (18-44; 45-59; 60-74; ≥75 years), sex, and Charlson comorbidity index 
(excluding the renal disease score). 
3.8.2 Statistics in Study II 
For ORs of death and ICU admission during hospitalization in patients with different 
kidney function, we used a mixed-effects logistic regression model to set multiple 
hospitalizations within a patient as a cluster and patients as a random effect. 
For the length of hospital stay and estimation of total medical cost, we used generalized 
linear regression models. For this analysis, we did not adjust for the cluster effect within 
patients since we considered any hospital stay as an independent statistical unit. Given 
the inflation rate changes over time, we compared medical expenses between those with 
and without CKD adjusted for inflation rate based on costs in 2012. 
3.8.3 Statistics in Study III 
We used multinomial logistic regression marginal prediction to estimate the age- & sex-
adjusted cause-specific death proportions. Cox regression models were adjusted for age 
groups, sex, and Charlson comorbidities index (excluding renal score), presented at 
different time points after admission (7 days after admission, 28 days after admission, 
90 days after admission and 365 days after admission). The association of kidney 
  25 
function and cardiovascular-related death was examined by a competing risk analysis 
(Fine and Gray proportional subdistribution hazards models) (123).  
3.8.4 Statistics in Study IV 
For each outcome measure of interest, random-effects meta-analysis was used to pool 
relative risks (RRs) for the dichotomous composite outcome (infection-related 
mortality, infection-related hospitalizations and any non-hospitalized-fatal infections) in 
order to determine the effect of different levels of 25(OH)D (high/normal vs. low), or 
according to use of vitamin D versus placebo/no use.  
We performed additional empirical Bayes meta-regression models in studies addressing 
the use of vitamin D as the exposure. These included types of administration (oral or 
intravenous) and study sample size (<500 or ≥500 participants) and types of dialysis 
therapy (HD or PD). The presence of small study effects and publication bias was 
evaluated by Egger regression asymmetry analysis (124). 
 
3.9 ETHICAL PERMISSION 
The ethics board committee of GDHCM provided ethical approval for Studies I, II and 
III (B2016-194-01). Informed consent was not needed since the studies involved 
analysis of anonymized existing data and records. The study was carried out in 
accordance with the Declaration of Helsinki, International Ethical Guideline for 
Biomedical Research Involving Human Subjects. Study IV was a systematic review 
and meta-analysis. Since all the data were extracted from the published literature, an 
ethical permit was not required. 
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4 MAIN FINDINGS 
The main findings derived from Studies I-IV are summarized and presented below. 
The section is divided into three main sub-sections: Microbial patterns (Study I), 
outcomes (Study II & Study III) in non-dialysis patients hospitalized with infections 
and the role of vitamin D in infection risk in those under chronic dialysis (Study IV). 
4.1 MICROBIAL PATTERN OF INFECTIONS IN PATIENTS WITH 
DIFFERENT KIDNEY FUNCTION (STUDY I)  
4.1.1 Microbial pattern  
Among 7,228 first positive microbial cultures, Gram-negative (G-) bacteria were the 
predominant detected bacteria, followed by Gram-positive (G+) bacteria, 
Mycoplasmataceae and fungi. Compared to patients with eGFR 60-104 ml/min/1.73m2 
(reference group), the proportion of G- bacteria decreased (from 68% to 63%) across 
decreasing eGFR strata, while the proportion of G+ increased (from 14% to 18%) 
(Figure 4).  
 
Figure 4. The pattern of the first positive microbial culture by different eGFR categories in 7,228 patients 
hospitalized with infections in four hospitals of Guangzhou, China 
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4.1.2 MDROs pattern 
In 2,565 MDROs, it was observed that different eGFR categories had different positive 
culture patterns. G+ MDROs increased while G- MDROs decreased from the group of 
eGFR between 60-104 ml/min/1.73m2 (Figure 5). 
 
Figure 5. The pattern of gram positive and gram negative multi-drug resistant organisms (MDROs) by 
different eGFR categories 
4.1.3 The odds ratio of MDROs 
The crude proportions of MDROs in the first positive cultures were 49.2%, 49.9%, 
53.5% and 58.0% in patients with eGFR ≥105, 60-104, 30-59 and <30 ml/min/1.73m2, 
respectively. 
The results of multivariable logistic regression models show that the odds of MDROs 
increased as eGFR category decreased. Compared to eGFR 60-104 ml/min/1.73m2 
(reference), the odds of infections by MDROs was 19% and 41% higher in those with 
eGFR between 30-60 ml/min/1.73 m2 [Adjusted odds ratio (AOR): 1.19, 95% 
Confidence interval (CI):1.02-1.38, P=0.02] and eGFR <30 ml/min/1.73 m2 (AOR: 
1.41, 95% CI:1.12-1.78, P< 0.01), respectively. The trends persisted in subgroup 
analysis across sex, age group, single pneumonia, single urinary tract infections, sepsis, 
health-care-associated infections, community-acquired infections and in patients with or 
without diabetes, although they did not reach statistical significance (Figure 6).  
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Figure 6. 
Odds ratio of MDROs in the first positive culture by patient characteristics and eGFR categories. Sex subgroup adjusted by age and Charlson comorbidity index; Age subgroup adjusted by sex and 
Adjusted by Charlson comorbidity index; The rest of the subgroups adjusted by age, sex and Charlson comorbidity index. *MDROs: multi-drug resistance organism; Defined by the following bacteria: 
Staphylococcus aureus, Enterococcus spp., Enterobacteriaceae, Pseudomonas aeruginos, Acinetobacter spp.; Resistance to three or more antimicrobial classes; IRH: infection-related hospitalization.   
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4.2 OUTCOMES IN PATIENTS HOSPITALIZED WITH INFECTIONS AND 
DIFFERENT KIDNEY FUNCTION (STUDY II & STUDY III) 
4.2.1 Intensive care admission (Study II) 
ICU admission rates were 5.5% and 12.2% in non-CKD and CKD patients, respectively. The 
odds of ICU admission were more than two times higher among patients with CKD 
(AOR=2.18; 95% CI 1.64-2.91). A similar pattern was observed for both HAIRHs 
(AOR=2.48; CI 1.08-5.70) and CAIRHs (AOR=2.01; 95% CI 1.34-3.02). We further 
analyzed single infection categories and found that the increased odds of ICU admission in 
patients with CKD remained statistically significant for pneumonia (OR=2.53; 95% CI 1.64-
3.88). 
4.2.2 In-hospital medical cost and length of hospital stay (Study II) 
The median length of hospital stay (LOHS) for CKD patients was 11 [8-15] days, which was 
statistically significantly longer (p<0.001) than the LOHS for non-CKD patients, 10 [7-14] 
days. Compared with non-CKD patients, medical expenses in patients with CKD were higher 
by a median of 2400 RMB (around 350 USD) per hospitalization, corresponding to 20.0% 
higher in total medical expenses adjusted for inflation rate based on costs in 2012.  
4.2.3 Mortality (Studies II, III) 
4.2.3.1 In-hospital mortality (Study II) 
A total of 115 patients (5.9%) in the CKD group and 166 (3.8%) non-CKD patients died in-
hospital. The odds of in-hospital mortality were, therefore, higher among patients with CKD 
(odds ratio, adjusted OR=1.41; 95% CI 1.02-1.96). In subgroup analysis, ORs for in-hospital 
mortality were higher among patients with CKD compared with non-CKD patients in 
CAIRHs, pneumonia, UTIs, although not statistically significant. 
4.2.3.2 Cardiovascular mortality and all-cause mortality post-discharge (Study III) 
During a median follow-up period of 2 years and five months, 4,781 out of 40,524 patients 
died. Using multivariable Cox proportional hazards model, all-cause mortality increased with 
the declining eGFR category. Compared to patients with eGFR values >60 mL/min/1.73m2, 
the hazards of all-cause mortality were 19% higher in those with eGFR values between 30-60 
mL/min/1.73m2 (adjusted HR: 1.19, 95% CI 1.11-1.28, P<0.01) and 73% higher in those with 
eGFR values < 30 mL/min/1.73m2 (adjusted HR: 1.73, 95% CI 1.59-1.88, P<0.01). In the 
competing risk model, the corresponding sub-distribution HRs for cardiovascular-related 
mortality were 2.15 (95% CI 1.85- 2.50, P<0.01) in patients with eGFR between 30-59 and 
3.19 (95% CI 2.68 - 3.80, P<0.01) in those with less than 30 mL/min/1.73m2, respectively.  
The risks of all-cause and cardiovascular-related death were highest in the first 7 days 
following admission and progressively declined thereafter, but remained significantly high at 
one year following admission (Table 2). 
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Table 2. Hazard ratio of all-cause mortality and sub-distribution hazard ratio of cardiovascular-
related mortality at different time points after admission. 
eGFR (mL/min/1.73m2) 
Overall 
( N=40,524) 
7 days after 
admission 
28 days after 
admission 
90 days after 
admission 
365 days after 
admission 
Hazard ratio of all-cause mortality* 
≥60 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference) 
30-59 1.19 (1.11 - 1.28) 2.11 (1.68 - 2.65) 1.54 (1.34 - 1.75) 1.28 (1.16 - 1.42) 1.21 (1.11 - 1.31) 
<30 1.73 (1.59 - 1.88) 4.29 (3.40 - 5.41) 2.37 (2.05 - 2.75) 1.86 (1.65 - 2.08) 1.68 (1.52 - 1.84) 
Sub-distribution hazard ratio of cardiovascular-related mortality** 
≥60 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference) 
30-59  2.15 (1.85 - 2.50) 3.42 (2.18 - 5.40) 2.95 (2.19 - 3.99) 2.84 (2.27 - 3.56) 2.46 (2.05 - 2.95) 
<30 3.19 ( 2.68 - 3.80) 5.22 (3.17 - 8.60) 4.60 (3.32 - 6.39) 4.30 (3.35 - 5.52) 3.78 (3.08 - 4.63) 
*Cox model: Adjusted for age, sex and Charlson 
comorbidity index.    
**Competing risk cause-specific model: Adjusted for age, sex and Charlson 
comorbidity index. 
   
4.2.4 Cause of death (Study III) 
During follow-up, 4,781 patients who hospitalized with infections died due to cancer 
(43.8%), cardiovascular disease (21.5%), acute infections (14.0%), chronic kidney disease 
(5.1%) or other causes (14.0%). The cause of death was missing in 1.6% of cases. The 
proportion of patients dying due to cardiovascular disease increased as the eGFR decreased. 
(Figure 7) Among participants with eGFR>60 mL/min per 1.73m2, cancer-related death was 
the most common cause of death: 55.3% (95% CI, 53.5% to 57.0%), which was consistent 
after adjustment for age and sex. For participants with eGFR values between 30-59 mL/min 
per 1.73m2, cardiovascular disease was the most common cause of death, accounting for 
32.5% (95% CI, 29.8% to 35.4%). After adjustment for age and sex, cancer was the most 
common cause of death in this category: 36.0% (95% CI, 33.1% to 38.9%). Among those 
with eGFR values <30 mL/min per 1.73m2, CVD was the most common cause of death, 
accounting for 29.1% (95% CI, 25.9% to 32.5%), which remained similar after adjustment 
for age and sex.  
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Figure 7. Unadjusted relative percentages for death by all-cause and eGFR. CVD: cardiovascular disease; CKD: 
chronic kidney disease.  
 
4.3 ROLE OF VITAMIN D IN RELATION TO INFECTIONS IN PATIENTS ON 
DIALYSIS (STUDY IV)  
Of 2,440 reports identified, 17 studies met the inclusion criteria, all with moderate quality. 
They included 6 cohort studies evaluating 25(OH)D serum concentrations (N=5,714) and 11 
(2 RCTs and 9 observational studies) evaluating the use of vitamin D (N=92,309). 
4.3.1 25(OH)-Vitamin D concentration and the risk of infection-related outcomes 
Compared to individuals with low serum levels of 25(OH)D, the pooled adjusted risk for 
composite infections was 39% lower (RR= 0.61, 95% CI 0.41-0.89, all were cohort studies) 
in those with high/normal levels, with moderate heterogeneity (I2= 60.5%, P=0.03) (Figure 
8A).  
In patients undergoing peritoneal dialysis, the risk of peritoneal dialysis-related infections 
was 66% lower (RR=0.34, 95% CI 0.20-0.58) in those with high/normal levels of 25(OH)D 
than in those with low levels, with minimal heterogeneity (I2= 0%, P=0.71). In patients 
undergoing hemodialysis, the risk of infection-related mortality was 12% lower (RR=0.88, 
95% CI 0.70-1.08) in those with high/normal levels of 25(OH)D, with minimal heterogeneity 
(I2= 0%, P=0.43).  
≥60          
(n=2,964)
30-59
(n=1,088)
<30
(n=729)
Missing (%) 1.3 1.9 2.3
Other causes of death (%) 13.7 14.9 14.1
CKD (%) 2.7 2.8 18.0
Common acute infections (%) 11.5 17.8 18.5
CVD (%) 15.6 32.5 29.1
Cancer (%) 55.3 30.1 18.0
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Cancer (%) CVD (%)
Common acute infections (%) CKD (%)
Other causes of death (%) Missing (%)
  33 
Publication bias was indicated in included studies investigating the level of 25(OH)D (P= 
0.007 in Egger’s test). 
Figure 8．Forest plot using the DerSimonian and Laird random-effects model：(A) The meta-association between 
high/normal versus low level of 25(OH)D and risk for infection-related outcomes; All the included studies were cohort 
studies; (B) The meta-association between use and non-use of vitamin D and risk for infection-related outcomes by study 
design; The observational study group included cohort and case-control studies exploring the association between the use of 
Vitamin D Receptor Agonists (VDRA) and risk for infection-related outcomes. The randomized controlled trials explored the 
association between supplemental nutritional vitamin D and risk for infection-related outcomes. 
4.3.2 Use of vitamin D and the risk of infection-related outcomes 
The pooled adjusted risk for infection-related outcomes was 41% lower in those who used 
vitamin D (nutritional supplement or VDRA) (RR=0.59, 95% CI 0.43-0.81) compared to 
those who did not, with high heterogeneity (I2= 91.1%, P<0.001) (Figure 8B).  
There was no statistically significant difference in infection-related outcomes between 
supplemental nutritional vitamin D users and non-users (RR=1.22, 95% CI 0.74-2.01, all 
were RCTs, Figure 8B). The pooled adjusted risk for infection-related outcomes was 48% 
(B) Use VS. non-use of Vitamin D 
(A) High/normal level VS. Low level of 25(OH)D 
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lower in those who used VDRA (RR=0.52, 95% CI 0.36-0.73, all were observational studies, 
Figure 3), with high heterogeneity (I2=92.6%, P<0.001). 
A similar association was observed in a meta-analysis of seven cohort studies, which 
explored the use of VDRA on the risk of infection-related outcomes. Meta-regression 
analyses suggested that PD patients in studies with larger sample sizes and using intravenous 
VDRA had lower RRs as compared with their counterparts (Table 4). 
Publication bias was not indicated in included studies investigating the use of vitamin D 
(P= 0.12 in Egger’s test). 
Table 4. Meta-regression Analyses on Association between Use of Vitamin D Receptor Activator 
and Risk of Infection-related Outcomes 
Use VS non-use of VDRA No. of Studies Empirical Bayes Metaregression Pooled HR (95% CI) P I2,% 
All infection-related outcomes 
    
Oral vs. Intravenous 9 0.66 (0.24-1.80) 0.36 86.50% 
HD vs. PD 8 0.61 (0.20-1.83) 0.32 93.40% 
Sample size <500 patients vs ≥ 500 9 0.31 (0.09-1.09) 0.06 93.00% 
 
Non-fatal infections 
    
HD vs. PD 5 0.57 (0.06-5.53) 0.49 76.97% 
Sample size <500 patients vs ≥ 500 5 0.27 (0.04-1.82) 0.12 86.42% 
VDRA: Vitamin D Receptor Activator; HD: hemodialysis; PD: peritoneal dialysis; CI: confidence interval; HR: hazard ratio 
  35 
5 DISCUSSIONS 
5.1 SUMMARY OF MAIN RESULTS: WHAT WAS KNOWN BEFOREHAND AND 
WHAT THESE STUDIES HAVE ADDED 
The studies included in this thesis investigated the antibiotic resistant patterns of pathogens as 
well as short- and long-term outcomes of patients with different kidney functions during and 
after hospitalization with infections. They also explored the role of vitamin D in the prevention 
of future infections in patients with chronic kidney disease. We found that the proportion of G- 
bacteria decreased, while the proportion of G+ increased across decreasing kidney function 
categories. Poorer kidney function at the time of hospital admission was associated with a 
higher probability of contracting MDROs (Study I). In those hospitalized with infections, CKD 
patients have increased odds of in-hospital deaths and ICU admissions, resulting in higher 
health care resource consumption (longer hospital stay and higher medical costs), compared 
with patients with normal renal function (Study II). Lower kidney function on admission was 
associated with significantly increased hazards of all-cause and cardiovascular-related mortality 
in those hospitalized with infections (Study III). Data from patients undergoing chronic 
dialysis indicated that the risk of infection-related outcomes was lower in patients with higher 
serum levels of 25(OH)D. Furthermore, the use of vitamin D, particularly vitamin D receptor 
activators, was associated with a lower risk of infection-related outcomes in this population 
(Study IV). 
5.1.1 MDROs in patients with CKD  
5.1.1.1 The underlying mechanism of association between MDROs and CKD 
The underlying mechanisms that could explain the association between reduced kidney 
function and MDROs might include: 1) Immune dysfunction predisposes patients with CKD to 
infections (125, 126); 2) Higher exposure to antibiotics (either prescribed by physicians or self-
prescribed) due to susceptibility to infections, drive antibiotic resistance (127); 3) Patients with 
more severely reduced renal function had more frequent contact with healthcare personnel and 
environments (e.g. hospitals) (28). 
5.1.1.2 MDROs in dialysis and non-dialysis CKD patients 
The presence of infections by MDROs in those requiring dialysis was well documented prior to 
this study. MRSAs were the most reported MDROs. In a study from the US, 10,517 (14.5%) 
out of 72,444 invasive MRSA infections were among dialysis patients (128). Among those on 
dialysis, a meta-analysis by Zacharioudakis et al. reported that the estimated prevalence of 
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MRSA colonization was 6.2% (95% CI 4.2% to 8.5%) (63). Of haemodialysis patients 
colonized with MRSA, 19% of the hemodialysis patients colonized with MRSA developed an 
MRSA infections within 6–20 months. The relative risk of MRSA bacteremia has been found 
to be approximately 100-fold higher among dialysis patients compared to the general 
population (128). The prevalence of colonization of MRSA was more common in patients on 
hemodialysis than in those on peritoneal dialysis (7.2% in HD than 1.3% in PD) (63). Shorr et 
al. documented that long-term hemodialysis was an independent risk factor associated with 
infections due to antibiotic-resistant bacteria (129).  
In terms of VRE, a meta-analysis of dialysis patients by Zacharioudakis et al. reported that the 
pooled prevalence of VRE colonization was 6.2% (95% CI, 2.8%-10.8%) (62). Recent use of 
any antibiotic, particularly vancomycin, and recent hospitalization significantly increased the 
possibility of a VRE-positive surveillance culture (62). 
MRSA and VRE are the antimicrobial-resistant bacteria that have been most extensively 
investigated in the dialysis population. Infections caused by multidrug-resistant gram-negative 
bacteria (MDR-GNB) is becoming a concern. Among dialysis patients, MDR-GNB accounted 
for approximately 25% of isolates in bloodstream infections (130, 131). A study found that the 
prevalence and incidence of colonization with MDR-GNB were greater than those of 
colonization with MRSA or VRE in an outpatient hemodialysis facility in the United States 
(132).  
The findings of Study I showed that higher odds of infections caused by MDROs were 
observed as the eGFR declined below 60 ml/min/1.73m2. The results of this thesis have 
contributed with the suggestion that the association with MDRO extends to those with less 
severe levels of reduced renal function who do not require dialysis.  
5.1.1.3 Association between MDROs and CKD in the context of China 
Our study in China showed a higher prevalence of MDRO infections in non-dialysis CKD 
patients than what has been reported in studies from Western countries (Study I). These studies 
conducted in Western countries only reported the prevalence of single colonized resistant 
bacteria, such as MRSA. Johnson et al reported that 21.6% of hospitalized dialysis patients 
were colonized with MRSA in the US (133). The high prevalence of resistant bacteria in our 
study was comparable to that of other studies from China (95, 134). Yang et al reported that the 
percentage of Staphylococcus Aureus identified as MRSA was 73.5% and the percentage of 
Acinetobacter Baumannii isolates identified as multidrug-resistant one was 77.8% in China in 
2015 (134). China is one of the countries in the world with high total antibiotic prescribing 
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(135, 136).  Misuse and overuse of antibiotics are driving forces of antibiotic resistance. Self-
prescribing and over-prescribing of antibiotics were prevalent in China before stringent 
antimicrobial stewardship policies were implemented in 2012 (137). These policies may take 
some time to take effect in terms of containing the high prevalence of MDROs in hospitalized 
patients.  
The finding of an association between kidney function and MDROs infections is of potential 
clinical relevance. The main clinical application of this study lies in the need to consider the 
presence of renal dysfunction at admission as a signal to pay closer attention to microbial 
culture results, given that identified pathogens may be potentially resistant to initial antibiotics. 
Therefore, subsequent modification of the current therapy is needed if resistance to the current 
therapy exists. Our study also identifies that patients with impaired renal function as a high-risk 
group for MDROs infections, with the implication that those patients are in need of close 
monitoring.  
5.1.2 Outcomes in patients hospitalized with infections and CKD 
The results of this thesis showed that patients with CKD had higher mortality, a higher rate of 
ICU admission, longer hospital stay and higher medical costs when they were hospitalized with 
infections, as compared to patients with normal renal function (Studies II & III).  
5.1.2.1 Mortality in patients hospitalized with infections and CKD 
Increased mortality associated with reduced renal function has also been observed in previous 
studies (29, 34, 35, 37, 111, 138-142). The Cardiovascular Health Study reported that patients 
with CKD had a 2-fold greater risk of infection-related mortality (138). This association was 
further confirmed in the Third National Health and Nutrition Examination Survey (NHANES 
III) (139). In that study, it was found that not only reduced eGFR, but also albuminuria was 
associated with increased risk for infection-related mortality (139). In a study conducted in 
nursing homes in Hong Kong, CKD stage 3B and stage 4/5 CKD were independent predictors 
of infection-related mortality in adults with a median age of 80 years (111). 
The association between reduced kidney function and mortality persisted in patients who had 
specific infections, such as bloodstream infections (35), sepsis (140) and pneumonia (29, 34, 
142). In a cohort of patients 66 years or above, the risk of death within 30 days of onset of 
community-acquired bloodstream infections was 4.1 times higher in those with an eGFR less 
than 30 mL/min/1.73m2 compared to those with an eGFR of 60 mL/min/1.73 m2 or higher (35). 
In a Canadian study, compared with participants with an eGFR of 60 to 104 mL/min/1.73 m2, 
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an age-dependent inverse relationship also was observed between eGFR and risk of 30-day 
death from pneumonia (34). In a cohort study from the UK, eGFR <30 mL/min/1.73 m2 was a 
risk marker of higher 28-day mortality for pneumonia (RR 1.27: 95% CI 1.12-1.43) and sepsis 
(RR 1.32: 95% CI 1.07-1.64) (29). 
The results of this thesis showed that lower eGFR on admission was associated with 
significantly increased hazards of all-cause mortality in patients hospitalized with infections. 
These heightened risks of mortality were highest within 7 days, but remained significantly 
elevated 1 year following admission. Because of higher mortality in patients hospitalized with 
infections, analysis of the cause of death in these patients might help risk stratification and help 
in the planning of intervention strategies.   
5.1.2.2 Cause of death in patients hospitalized with infections and CKD  
Regarding the cause of death in patients with CKD, a study from Canada used administrative 
health care data and linked laboratory information to show that the most common cause of 
death for those with eGFR less than 60 ml/min per 1.73 m2 was cardiovascular disease (116). 
Similarly, a study from the U.S. found that cardiovascular diseases were the main causes of 
death in patients with CKD. After adjusting for covariates, every 5 ml/min per 1.73 m2 decline 
in eGFR was associated with a 1.1 fold higher risk of death due to cardiovascular disease (HR, 
1.10; 95% CI, 1.08 to 1.12)  (143). However, there was little exploration about the cause of 
death in patients hospitalized with infections. The results of the thesis showed that CVD was 
the leading cause of death in patients with eGFR less than 60 ml/min per 1.73 m2 during or 
after hospitalization with infections (Study III).  
Previous studies have documented that acute infections triggers a 2 to 8-fold increase in the risk 
of CVD within the first 30 days (97) as well as after 10 years (98, 144-146). A cohort study 
from Canada showed that an infectious episode was independently associated with increased 
risks of mortality and CVD in those with advanced CKD (eGFR between 15 and 45 
mL/min/1.73m2) (43). What is new in our study is that we observed that CVD-related mortality 
following infections was incrementally higher in those with eGFR<60 mL/min/1.73m2, not just 
in those with advanced CKD (Study III). 
5.1.2.3 Other outcomes in patients hospitalized with infections and CKD 
Our study builds on previous findings that CKD is a risk factor for poor outcomes of IRHs in 
terms of more frequent admissions to ICU, longer hospital stays and higher medical costs, in 
addition to higher mortality (Study II). This finding is clinically important and relevant from a 
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health policy perspective. Infection is still one of the main causes of hospitalization, consuming 
a large amount of health-care resources. Our findings highlighted that patients with reduced 
renal function had poor in-hospital outcomes and higher medical costs. They will inform 
policymakers that more resources need to be allocated to infection prevention, especially in 
those with reduced renal function. In the context of DRGs funding system (or so-called single 
disease reimbursement payment) in China, reimbursement to the hospital is the same if patients 
are admitted with the same illness, regardless of their comorbidities (87) (147). Our findings 
suggest that comorbidities, like CKD, should be considered.  
5.1.3 The role of vitamin D in relation to infections in patients with CKD  
5.1.3.1 The potential mechanism of association between vitamin D and infections 
A biologically plausible mechanism by which vitamin D impacts the risk of infections might lie 
in its role in the innate and adaptive immune systems (148). In the innate immune system, 
vitamin D promotes the production of β-defensin 2 and cathelicidin which enhances the 
capacity for autophagy via toll-like receptor activation (149). In the adaptive immune system, 
vitamin D suppresses the maturation of dendritic cells and weakens antigen presentation (148).  
5.1.3.2 Association between vitamin D and infections in the non-dialysis population 
Previous studies from the general population have suggested an independent association 
between low serum concentrations of 25(OH)D and susceptibility to respiratory tract infections, 
as well as a potentially protective effect of vitamin D against infections (101, 150, 151). In the 
NHANES III, 25(OH)D levels <30 ng/mL were associated with 56% higher odds of 
community-acquired pneumonia [OR: 1.56; 95%  CI: 1.17-2.07] compared to levels >/=30 
ng/mL(151).  
Not only lower levels of 25(OH)D, but also lower levels of 1,25-dihydroxy vitamin D 
(1,25(OH)2D, the activated form of vitamin D) have been associated with infections. In a 
cohort with a 9.5-year follow-up of 3,292 community-dwelling Japanese subjects, it was 
observed that death due to respiratory infections increased significantly with lower serum 
1,25(OH)2D levels. In the stratified analysis, the association between lower serum 1,25(OH)2D 
levels and the risk of respiratory infection death was stronger in non-dialysis patients with an 
eGFR <60 mL/min/1.73 m2 as compared to those with eGFR >/=60 mL/min/1.73 m2 (152).  
5.1.3.3 Association between vitamin D and infections in the dialysis CKD population 
In dialysis populations, however, the evidence of the association between 25(OH)D and 
infections were conflicting from observational studies (55, 56, 102, 104, 105, 107). In the meta-
 40 
analysis of this thesis, it was found that the risk of composite infection-related outcomes (risk 
of infections, infection-related hospitalization, infection-related death) was lower in patients 
with higher serum levels of 25(OH)D. In sub group analysis according to different dialysis 
modalities, we found that this association was not consistent in studies involving hemodialysis 
patients. One reason for this inconsistency might be that studies involving HD used different 
infection-related outcomes (mortality or hospitalizations). Studies involving PD patients 
showed a consistent association between lower level of 25(OH)D and peritoneal dialysis-
associated peritonitis. 
If the association between vitamin D and infections in dialysis patients was causal, we would 
expect vitamin D supplementation to lower the risk of infections in this population. The meta-
analysis results of this thesis showed that VDRA, but not nutritional supplements, were 
associated with lower risk of infections. This discrepancy might be related to differences in 
outcomes ascertainment (infection was not the primary outcome) or in sample size (only 2 
studies of nutritional vitamin D supplements). The question remains whether nutritional 
vitamin D supplementation would reduce the risk of infections. Randomized control trials in 
the non-dialysis population report inconsistent findings of vitamin D supplementation on the 
risk of infections (106, 153). This discrepancy of associations might be related to genetic 
variation in vitamin D metabolism or signaling, which may, in turn, modify the infection 
prevention effects of vitamin D (154). It should be noted that it is the 1,25-dihydroxy vitamin D 
(1,25(OH)2D), which is a direct inducer of antimicrobial peptide gene expression, not 25(OH)D 
(155, 156). Therefore, it might make sense that nutritional vitamin D supplements exert less of 
an effect on infections than VDRA (149).  
Overall, the hypothesis that vitamin D supplementation lowers the risk of infections in dialysis 
patients is yet to be confirmed in randomized controlled trials. 
 
5.2 METHODOLOGICAL CONSIDERATIONS 
5.2.1 Strengths  
Studies I, II and III were based on real-world electronic medical data extracted from clinical 
practice. Many previous studies have analyzed registry data with large sample sizes, but lack 
detailed information about clinical outcomes and the economic burden of hospitalizations with 
infections. We were able to 1) comprehensively examine the spectrum of infections, pattern of 
bacteria and drug sensitivity (Study I); 2) explore the associations between kidney function and 
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a large range of in-hospital outcomes, furthering our understanding of how certain 
characteristics predispose to in-hospital death, ICU admission, longer hospital stays and higher 
medical costs (Study II); 3) link with the death registry and trace causes of death with a low 
percentage of missing data (1.6% in Study III), furthering our understanding of what 
characteristics predispose to specific causes of death. 
In our systematic review, we were able to capture as many relevant studies as possible via 
comprehensive searches of four English databases and three Chinese databases; We not only 
investigate how level of vitamin D [25(OH)D] has an impact on the risk of infections, but also 
explore the use of vitamin D (both nutritional supplementation and VDRA). This allowed a 
better understanding of the association of vitamin D with infection-related outcomes, from 
phenomenon to intervention (Study IV).    
5.2.2 Limitations  
The results should be interpreted considering the following limitations. 
5.2.2.1 Selection bias 
5.2.2.1.1 Measurement of kidney function 
In Study II, we included patients with at least one eGFR measurement in outpatient care 
between one and twelve months before IRHs, to estimate kidney function. The reason why we 
used outpatient creatinine to estimate kidney function was to avoid the potential shift of eGFR 
following hospital admission. However, not all patients hospitalized with infections had an 
outpatient creatinine measurement. In this study, only 11% of all patients hospitalized with 
infections had outpatient eGFR measurement. Thus, selection bias can not be ruled out. Patients 
with outpatient eGFR measurements might seek healthcare more frequently than those who do 
not, or they might be in poorer health. Instead of using eGFR from outpatient visits, we used 
eGFR at admission to estimate renal function in Studies I and III, capturing more than 95% of 
patients hospitalized with infections. Thus, the representativeness of these study populations 
might be better.   
5.2.2.1.2 Outcome assessment 
In Study I, the main study outcome was the presence of MDROs in the first positive culture. 
The presence of MDROs was influenced by culture positive rate, previous antibiotic use, 
hospitalization or admission from a nursing home (157-159). There was no significant 
difference in culture positive rates across different eGFR categories in our sample. However, 
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we did not have access to a regional registry that allowed us to identify previous antibiotic use 
or hospitalizations. 
In Study II, all in-hospital outcomes (in-hospital death, ICU admission, length of hospital stay 
and medical costs) were recorded in the EMR database. There were no missing data. Thus, 
selective bias due to missing outcomes is unlikely.  
In Study III, we linked the EMR database with the death registry with only 1.6% of missing 
data about the cause of death. Selective bias due to missing death status data is thus unlikely. 
However, the frequency of the death data updated is a concern.  
In Study IV, we tried our best to identify all relevant articles including those with negative 
results and grey literature, to avoid selective reporting. Although the tests for publication bias 
of studies investigating the use of vitamin D were insignificant, its possibility cannot be 
confidently excluded from observing the funnel plot. 
5.2.2.2 Information bias 
5.2.2.2.1 Classification of kidney function groups 
In Study II, we only used the closest serum creatinine 1-12 months before hospitalization as a 
proxy for kidney function, assuming kidney function to be relatively stable over one year. 
Misclassification might, however, still exist due to any change of kidney function during this 
period.  
In Study I and III, we used a single measurement of eGFR at admission to define renal 
function, which may have resulted in misclassification of true eGFR as patients’ renal function 
might not have been in steady state at the time. Thus, it was not possible to determine with 
certainty whether patients with low eGFR values at hospital admission had acute kidney injury, 
chronic kidney disease or a combination of the two. A sensitivity analysis examining the 
relationship between eGFR values determined 1-12 months prior to hospitalization and 
MDROs demonstrated consistent findings (Study I). Similar sensitivity analysis demonstrated 
consistently higher hazard ratios for all-cause and cardiovascular mortality in those with low 
eGFR values at admission, regardless of whether or not reduced renal function existed at a prior 
outpatient visit (Study III).  
5.2.2.2.2 Ascertainment of outcomes 
In Study I, a positive culture could also be related to colonization or contamination and false 
positives might exist. Frequent cultures might increase the rate of a positive culture. However, 
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there was no difference in culture positive rates across different eGFR categories. We assume 
this to be a non-differential classification bias.    
There is no universally accepted scheme for classifying cause of death. The groupings that we 
used in Study III were based on previous studies (117). However, it is unlikely that the cause 
of death would be reported differently due to the kidney function of the patients. We assume 
this to be a non-differential classification bias. 
5.2.2.3 Residual confounding 
Despite adjustment for relevant confounders, we cannot exclude the potential effect of residual 
confounding factors, such as smoking, alcohol consumption, blood pressure, body mass index, 
the severity of systemic inflammation, or medication (e.g., angiotensin converting enzyme 
inhibitors), which were not available in our database.  In Studies I, II and III, very few 
patients had at least one record of albumin-creatinine ratio or protein creatinine ratio. This 
introduces additional residual confounding in view of preceding studies suggesting increased 
infection risk in patients with normal eGFR with albuminuria (36).  
In Study IV, we used the most adjusted RR presented in the evaluated studies, but the 
consistency of our results is affected by their implicit residual confounding. The findings 
cannot prove causality and residual or unmeasured confounding cannot be ruled out. 
5.2.2.4 External validity 
The findings of Studies I, II and III were from Guangzhou and generalization to other 
populations should be done with caution. We speculate that comparable associations may also 
be present in other populations with similar social status and income levels. 
Study IV was a meta-analysis of available data from chronic dialysis patients. Generalization 
to other CKD stages cannot be assumed and has yet to be confirmed in future studies. 
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6 CONCLUSIONS 
• Patients with non-dialysis dependent CKD hospitalized with infections: 
• Have a higher likelihood of having infections with multi-drug resistant organisms;  
• Have poorer in-hospital clinical outcomes, resulting in higher health-care resource 
consumption;  
• Are at significantly increased risk of all-cause and cardiovascular mortality during the 
following year.  
• In patients with CKD receiving chronic dialysis, lower serum levels of 25(OH)-vitamin D 
and use of vitamin D, particularly vitamin D receptor activators, were associated with a lower 
risk of infections.  
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7 IMPLICATIONS AND FUTURE RESEARCH 
7.1 IMPLICATIONS FOR CLINICAL PRACTICE 
Patients with impaired renal function are a high-risk group for contracting infections by multi-
drug resistant organism infections, in need of close monitoring. In patients hospitalized with 
infections, clinicians should consider the presence of renal dysfunction at admission as a signal 
to pay closer attention to the results of microbial culture, given that identified pathogens may be 
potentially resistant to initial antibiotics.  
Patients with reduced kidney function at admission have a high risk of cardiovascular-mortality 
during hospitalization and after one year. Heart status should be carefully monitored following 
the hospitalization of patients with infections, especially in those with reduced renal function 
and preexisting ischemic heart disease. 
Considering the consistent association between high/normal level of vitamin D and lower risk 
of infections in patients with CKD receiving chronic dialysis, strategies to increase the serum 
concentration of vitamin D, such as more sunshine exposure in a certain degree, may be 
encouraged. The use of vitamin D supplements (nutritional or vitamin D receptor activator) 
might also reduce the risk of infections in this population. When prescribing vitamin D 
supplements to these patients, however, their potential adverse effects, such as hypercalcemia 
leading to vessel calcification, should be considered. 
 
7.2 IMPLICATIONS FOR POLICY AND PUBLIC HEALTH 
As a part of China’ healthcare reform, DRGs (or so-called single disease reimbursement 
payment) has been introduced in some cities, such as Guangzhou. By definition, classification 
of cases in DRGs is based on principal and secondary diagnoses, type of treatment, patient age 
and sex, surgery, the existence of co-morbidities and complications, discharge status and the 
procedures performed (160). DRGs payment might work in simple situations such as for 
patients with appendicitis admitted for surgery. However, patients admitted to hospital for other 
reasons, such as infections, are more complex, presenting with different comorbidities, 
especially in the context of increased prevalence of non-communicable disease in China. In 
fact, the current payment system in China has not established a multi-faceted model that can 
cope with the complexity of DRGs. Under the current system, the government pays the same 
fee if patients are admitted with the same illness, regardless of their coexisting comorbidities 
(82, 147). The findings of our study indicate that patients hospitalized with infections have 
 48 
higher medical expenses if they also have CKD, which may justify adjustments to the policy of 
diagnosis-related group payment.  
As the global population is aging and kidney function declines with age, we foresee the 
population of CKD to increase in the future. Not only does infection in patients with CKD 
induce poor outcomes in this population, requiring more healthcare consumption, but patients 
with CKD can also be a reservoir of multi-drug resistant organisms, disseminating resistant 
bacteria to other populations and thus contributing to worldwide antibiotic resistance. Global 
attention to infections in patients with CKD should thus be encouraged and prioritized.  
 
7.3 IMPLICATIONS FOR FUTURE RESEARCH 
Given the significant impact of infections on patients with CKD, research into the underlying 
mechanisms of high infection risk in this population is warranted, together with identification 
of strategies to reduce the risk of infections. Also important to explore is how to raise 
awareness about the importance of infection prevention and associated strategies in the 
healthcare sector. Although we have observed consistent associations between vitamin D 
receptor activator and lower risk of infections in patients receiving dialysis, whether the same 
protection applies to non-dialysis CKD is not known and should be investigated in suitable 
trials. 
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10 APPENDIX 
Appendix Table S1. ICD-10 codes for different types of infections. 
The following discharge diagnoses were not considered in our study: pregnancy-related infections, delivery-related infections, oral/mouth infections, ear infections, eye infections, 
pancreatitis, thyroiditis, pituitary gland infections specified as chronic, chronic hepatitis B and C virus, HIV (human immunodeficiency virus), cholecystitis associated with 
cholelithiasis/choledocholithiasis, sexually transmitted infections, parasitic or protozoal diseases and device-dialysis related infection.
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Appendix Table S2. The link between infection diagnosis and culture sample. 
Discharge infection diagnosis Type of culture sample 
Respiratory tract infections Sputum, Nasopharyngeal swab 
Urinary tract infections (UTIs) Midstream urine 
Non-UTIs genitourinary infections Cervical swab, Vaginal Swab 
Bloodstream infections or sepsis; All types of sample 
Abdominal infections Stool, Bile, Ascitic fluid 
Skin and soft tissue infections Wound swab, Skin and soft tissue 
Nervous system infections; Cerebrospinal fluid 
Musculoskeletal infections Joint fluid, muscle tissue 
Cardiovascular infections Pericardial effusion 
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Appendix Table S3. ICD-10 codes for all causes of death 
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Appendix Table S4. Pubmed searching strategy 
#1 "Anti-Bacterial Agents"[Mesh] OR "Anti-Bacterial Agents" OR antibiotic* 
#2 amoxicillin OR ampicillin* OR bacitracin OR cephalothin OR cefazolin OR cefotaxime OR 
cefoperazone OR ceftazidime OR ceftriaxone OR cefuroxime OR chloramphenicol OR ciprofloxacin 
OR clarithromycin OR clindamycin OR cloxacillin OR colistin OR colimycin OR erythromycin OR 
flucloxacillin OR furazolidone OR "fusidic acid" OR gentamicin OR gramicidin OR imipenem OR 
"mafenide acetate" OR mupirocin OR natamycin OR neomycin OR nitrofurazone OR oxacillin OR 
penicillin OR piperacillin OR polymyxin OR rifam* OR "silver nitrate" OR "silver sulfadiazine" OR 
"sulfacetamide sodium" OR tobramycin OR amphotericin OR tazocin OR teicoplanin OR tetracycline 
OR trimethopri* OR sulfamethoxazole OR vancomycin 
#3 "Infection"[Mesh] OR "Infecti*" OR "infectious" OR "infection-related" 
#4 "Catheter-related infection"[Mesh] OR "Peritonitis"[Mesh] OR "Catheter-related infection" OR 
"Peritonitis" 
#5 "sepsis"[Mesh] OR sepsis OR "Systemic Inflammatory Response Syndrome"[Mesh] OR "Systemic 
Inflammatory Response Syndrome" OR sirs 
#6 "Bacterial Infections and Mycoses"[Mesh] OR "Virus Diseases"[Mesh] OR bacterial* 
#7 "pneumonia"[Mesh] OR "Respiratory Tract Infections"[Mesh] OR "respiratory tract infection*" OR 
"respiratory infection*" OR pharyngit* OR tracheit* OR bronchit* OR pneumon* OR "common 
cold"[Mesh] OR "common cold*" OR coryza OR influenza* OR flu OR "otitis media*" OR sinusit* OR 
tonsillit* OR laryngit* OR pharyngit* OR bronchit* OR pneumon* 
#8 cystitis[Mesh] OR "Urinary Tract Infections"[Mesh] OR pyelonephritis[Mesh] OR "cystitis*" OR 
"urinary tract infection*" OR "UTI*" OR pyelonephritis 
#9 ("1966/01/01"[Date - Publication] : "2017/12/30"[Date - Publication]) 
#10 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8) AND #9 
#11  "Vitamin D"[Mesh] OR "vitamin D" OR "vitamin d2" OR "vitamin d3" 
#12 "Cholecalciferol"[Mesh] OR "Calcitriol"[Mesh] OR "25-Hydroxyvitamin D3 1-alpha-
Hydroxylase"[Mesh] OR "Ergocalciferols"[Mesh] OR "Hydroxycholecalciferols"[Mesh]  
#13 "25-hydroxyvitamin D" OR "25-hydroxyvitamin d*" OR "1,25-dihydroxy Vitamin D*" OR "1alpha-
hydroxy Vitamin D3" OR "19-nor-1,25-dihydroxy Vitamin D*" OR "cholecalciferol*" OR 
"colecalciferol*" OR "hydroxycholecalciferol*" OR "falecalcitriol*" OR "calcitriol*" OR "alfacalcidol*" 
OR "alphacalcidol*" OR "calcipotriol*" OR "epicalcitriol*" OR "22-oxa-1alpha, 25-dihydroxy Vitamin 
D" OR "F6-1alpha, 25-dihydroxy Vitamin D*" 
#14   "25-Hydroxyvitamin D 2"[Mesh] OR "Calcifediol"[Mesh] OR Dihydrotachysterol[Mesh] OR 
"dihydrotachysterol*" OR "1alpha-hydroxyergocalciferol" OR "dihydrotachysterol*" OR "calciferol*" 
OR "doxercalciferol*" OR "dihydroxyvitamin D*" OR "hydroxyvitamin D*" OR "calcifediol*" OR 
"ergocalciferol*" OR "calcifediol lactol" OR "calcifediol lactone" 
#15 "maxacalcitol*" OR "oxacalcitriol" OR "paricalcitol*" OR "lexacalcitol*" OR "seocalcitol*" OR 
"VDRA" 
#16  ("1966/01/01"[Date - Publication] : "2017/12/30"[Date - Publication]) 
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#17  (#11 OR #12 OR #13 OR #14 OR #15) AND #16 
#18 "Kidney Failure, Chronic"[Mesh]) 
#19 "Renal Insufficiency, Chronic"[Mesh] 
#20 "chronic kidney disease" OR "renal failure*" OR "CRF" OR "kidney failure*" OR "renal insufficien*" 
OR "kidney dysfunction" OR "renal dysfunction" OR "reduced kidney function" OR "reduced renal 
function" OR "chronic kidney" OR "chronic renal" 
#21 "estimated glomerular filtration rate" OR "eGFR" OR "reduced eGFR" 
#22   "end-stage renal disease*" OR ESRD OR "End-Stage Kidney Disease" OR "ESKD" OR "CKD" OR 
"CKF" OR "CRD" OR "CRF" OR "ESKF" OR "ESRF" OR "uremia"[Mesh] 
#23  "predialysis" OR "dialysis" OR "haemodialysis" OR "hemodialysis" OR "dialysis*" OR "Renal 
Replacement Therapy"[Mesh] OR "Renal Dialysis"[Mesh] OR "Hemofiltration"[Mesh] OR 
"hemodialysis" OR "Hemofiltration" OR hemodiafiltration OR "peritoneal dialysis" OR "continuous 
renal replacement therapy" OR "CRRT" OR "Hemodialysis, Home"[Mesh] OR 
"Hemodiafiltration"[Mesh] OR "Hemofiltration"[Mesh] OR "Peritoneal Dialysis"[Mesh] OR "Peritoneal 
Dialysis, Continuous Ambulatory"[Mesh] 
#24 "CAPD" OR "CCPD" OR "APD" 
#25 "kidney transplant*" OR "Kidney Transplantation"[Mesh] 
#26 "glomerular disease*" OR "glomerular nephritis" OR "nephritis" OR "nephrotic syndrome*" OR 
"nephropathy" OR "podocyte disease*" OR "Proteinuria" OR "Albuminuria" OR "Proteinuria"[Mesh] 
OR "Albuminuria"[Mesh] 
#27 ("1966/01/01"[Date - Publication] : "2017/09/30"[Date - Publication]) 
#28 (#18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26) AND #27 
#29 #10 AND #17 AND #28 
 
